Evidence map›Paper›PMID 33042819›Full record

ArticleFrontiers in oncology2020

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible.

Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Enrica Bach, Sabine Leiblein, Yvonne Remane, Susanne Rieprecht, Sandra Otto, Anne-Sophie Kubasch, Gerhard Behre and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vladan VucinicUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Madlen JentzschUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Sebastian SchwindUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Enrica BachUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Sabine LeibleinUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Yvonne RemaneUniversity of Leipzig Medical Center, Pharmacy, Leipzig, Germany.
Susanne RieprechtUniversity of Leipzig Medical Center, Pharmacy, Leipzig, Germany.
Sandra OttoUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Anne-Sophie KubaschUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Gerhard BehreUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Michael CrossUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Uwe PlatzbeckerUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.
Georg-Nikolaus FrankeUniversity of Leipzig Medical Center, Clinic and Policlinic for Hematology and Celltherapy, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and treatment-related acute myeloid leukemia (tAML) after chemotherapy or radiation therapy for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the cases of four consecutive patients with AML-MRC or tAML who received CPX-351 as outpatient induction therapy immediately followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in complete remission and one in partial remission) and two patients received allo-HSCT in aplasia (one at 11 days and one at 52 days after the start of induction therapy with CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are alive and two are in remission. Further studies will help define and expand the role of CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to undergo allo-HSCT.

Indexed as

AML-MRCCPX-351hematopoeietic stem cell transplantationinduction therapyprognosistherapy-related acute myeloid leukemia

Identifiers

PMID33042819
PMCPMC7526474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.